Key result
Intracoronary recombinant tissue plasminogen activator infusion successfully treated a full-term newborn with coronary artery thrombus, sparing the patient from ECMO.
Why the study?
Neonatal myocardial infarction due to coronary thrombus is a rare cause of acute heart failure with high morbidity and mortality.
Case Report (n=1)
Intracoronary tPA combined with systemic circulation support may be a viable strategy to treat neonatal myocardial infarction while avoiding the complications of ECMO.
May offer ECMO alternative in neonatal MI; hypothesis-generating case report needing prospective validation.
Neonatal myocardial infarction due to coronary thrombus is a rare cause of acute heart failure and is associated with high morbidity and mortality. We present a rare case of a full-term newborn who developed coronary artery thrombus treated with intracoronary recombinant tissue plasminogen activator infusion while undergoing therapeutic hypothermia. Also, we describe a unique treatment strategy to support systemic circulation sparing the patient from neonatal extracorporeal membrane oxygenation and its complications. Neonatal myocardial infarction should be suspected and ruled out in sick newborns.
No takes yet. Share an insight, caveat, or question.
A 2021 study conducted a case report in Neonatal myocardial infarction due to coronary thrombus (n=1). Intracoronary recombinant tissue plasminogen activator infusion was evaluated. Intracoronary recombinant tissue plasminogen activator infusion successfully treated a full-term newborn with coronary artery thrombus, sparing the patient from ECMO.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: